Accessibility Menu
 
Cardiol Therapeutics logo

Cardiol Therapeutics

(TSX) CRDL

Current Price$1.89
Market Cap$215.91M
Since IPO (2018)-53%
5 Year-56%
1 Year+56%
1 Month+31%

Cardiol Therapeutics Financials at a Glance

Market Cap

$215.91M

Revenue (TTM)

$0.00

Net Income (TTM)

$33.82M

EPS (TTM)

$-0.39

P/E Ratio

-4.94

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$1.89

Volume

65,642

Open

$1.94

Previous Close

$1.89

Daily Range

$1.83 - $1.94

52-Week Range

$1.23 - $2.17

CRDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiol Therapeutics

Industry

Pharmaceuticals

Employees

23

CEO

David G. Elsley, MBA

Headquarters

Oakville, ON L6H 0G5, CA

CRDL Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-159%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-20.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$215.91M

Shares Outstanding

111.87M

Volume

65.64K

Short Interest

0.00%

Avg. Volume

121.33K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$34.32M

EBITDA

$34.21M

Operating Cash Flow

$23.85M

Capital Expenditure

$24.48K

Free Cash Flow

$23.88M

Cash & ST Invst.

$21.42M

Total Debt

$125.52K

Cardiol Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$25.98K

N/A

Gross Margin

0.00%

N/A

Market Cap

$215.91M

N/A

Market Cap/Employee

$12.00M

N/A

Employees

18

N/A

Net Income

$7.21M

+11.8%

EBITDA

$8.00M

+19.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$21.29M

-30.0%

Accounts Receivable

$226.19K

-37.4%

Inventory

$0.00

N/A

Long Term Debt

$87.18K

-30.5%

Short Term Debt

$38.35K

+16.2%

Return on Assets

-1.43%

N/A

Return on Invested Capital

-1.91%

N/A

Free Cash Flow

$5.23M

+6.6%

Operating Cash Flow

$5.23M

+6.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVE.VCannara Biotech Inc.
$1.89+6.18%
RX.VBioSyent Inc.
$14.93-2.10%
MSCL.TOSatellos Bioscience Inc.
$10.03+10.83%
JUSH.CNJushi Holdings Inc.
$0.72+2.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$65.18+0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.81+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$50.66+0.03%
PLTRPalantir Technologies
$132.37+0.03%

Questions About CRDL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.